Vanda to Present Tasimelteon Non-24 Phase III Data at Two Medical Meetings
-- Data to be presented at SLEEP 2013 27th Annual Meeting of the Associated
Professional Sleep Societies and the Endocrine Society's 95th Annual Meeting
WASHINGTON, May 30, 2013
WASHINGTON, May 30, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA)
(NASDAQ: VNDA) today announced that data from the Phase III studies of
tasimelteon in Non-24-Hour Disorder (Non-24) will be presented at SLEEP 2013,
the 27th Annual Meeting of the Associated Professional Sleep Societies, LLC
being held from June 1, 2013 through June 5, 2013 in Baltimore and the
Endocrine Society's 95th Annual Meeting (ENDO) being held June 15, 2013
through June 18, ^ 2013 in San Francisco. Non-24 is a serious and rare
circadian rhythm disorder that affects a majority of totally blind individuals
who lack light perception and cannot entrain (synchronize) their master body
clock to the 24-hour day.
Tasimelteon data at SLEEP 2013 will be presented as a late breaking abstract
and the data at ENDO 2013 will be presented in a poster and oral presentation.
The data presentation schedule is as follows:
-- SLEEP 2013 Baltimore
Late Breaking Abstract #005 June 5, 2013 at 12:15 PM-1:30 PM
-- ENDO 2013 San Francisco
SUN-134 June 16, 2013 at 1:45 PM – 3:45 PM
SUN-137 June 16, 2013 at 1:45 PM – 3:45 PM
About Non-24-Hour Disorder
Non-24 is a serious, rare, and chronic circadian rhythm disorder characterized
by the inability to entrain (synchronize) the master body clock with the
24-hour day-night cycle. Non-24 affects the majority of totally blind
individuals, or between 65,000 and 95,000 people in the U.S. Non-24 occurs
almost entirely in individuals who lack the light sensitivity necessary to
entrain the master body clock in the brain with the 24-hour day-night cycle.
Most people have a master body clock that naturally runs longer than 24-hours
and light is the primary environmental cue that resets it to 24-hours each
day. Individuals with Non-24 have a master body clock that continually
delays, resulting in prolonged periods of misalignment between their
circadian rhythms and the 24-hour day-night cycle, including the timing of
melatonin and cortisol secretion and the sleep-wake cycle. As a result of
this misalignment, Non-24 is associated with significant impairments in social
and occupational functioning, and marked subjective distress. For more
information on Non-24, please visit www.Non-24.com.
Tasimelteon is a circadian regulator in development for the treatment of
Non-24. Tasimelteon is a dual melatonin receptor agonist (DMRA) with
selective agonist activityat the MT1 and MT2 receptors.^ Tasimelteon's
ability to reset the master body clock in the suprachiasmatic nucleus (SCN)
results in the entrainment of the body's melatonin and cortisol rhythms with
the 24-hour day-night cycle. The patent claiming tasimelteon as a new
chemical entity extends through December 2022, assuming a 5-year extension to
be granted under the Hatch-Waxman Act. Tasimelteon has been granted orphan
drug designation for the treatment of Non-24 from both the U.S. and the
About Vanda Pharmaceuticals Inc.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the
development and commercialization of products for the treatment of central
nervous system disorders. For more on Vanda, please visit
Senior Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
Assistant Vice President
SOURCE Vanda Pharmaceuticals Inc.
Press spacebar to pause and continue. Press esc to stop.